Abstract: A system includes a server system that includes a processor and instructions stored in non-transitory machine-readable media. The instructions are configured to cause the server system to receive authentication information from a client device. The authentication information relates to a financial account of a user. The instructions are also configured to cause the server system to authenticate the user so as to associate the client device with the financial account of the user. The system also includes a financial notification circuit located on the client device. The financial notification circuit is configured to determine a location of the client device. The financial notification circuit is also configured to provide a notification on the client device alerting the client to not spend money at the location.

Abstract: A personal financial notification device includes a processor coupled to machine readable storage media having instructions stored therein. The instructions, when executed by the processor, cause the processor to receive a non-confidential status of a financial account of a user from a separate mobile device. The financial account is associated with the personal financial notification device. The instructions also cause the processor to display the non-confidential status of the financial account without requiring user authentication.

Abstract: Described are methods of treatment of a small cell lung cancer subject expressing Schlafen-11 (SLFN 11) with a Poly (ADP-ribose) polymerases (PARP) inhibitor or a pharmaceutically acceptable salt thereof. Specifically, the method comprising detecting SLFN 11 in a tumor cell sample from the subject, and administering effective amount of a PARP inhibitor, such as talazoparib or the tosylate salt of talazoparib, to the subject.

Abstract: The invention provides, inter alia, methods for methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with APCDD1 overexpression.

Abstract: The invention provides methods of monitoring differential gene expression of pharmacodynamic (PD) markers in a patient treated with a Cyclin Dependent Kinase Inhibitor (CDKI), methods of determining the sensitivity of a cell to a CDKI by measuring PD markers and methods of screening for candidate CKDI.

Abstract: A drain assembly comprising a rigid fixture body having a longitudinal axis, an intake opening adapted to conduct a fluid into the fixture body, the intake opening generally being oriented to point away from the longitudinal axis, an discharge opening adapted to conduct the fluid out from the fixture body, the discharge opening generally being oriented to point away from the longitudinal axis and the intake opening, a divider plate disposed in the rigid fixture body along the longitudinal axis, the divider plate adapted to divide an internal space of the rigid fixture body and form a generally U-shaped fluid-conducting passageway from the intake opening to the discharge opening, a clean-out opening in fluid communication with the passageway and generally being oriented to point away from the longitudinal axis and the discharge opening, and a removable cap adapted to close off the clean-out opening.

Abstract: The invention provides, inter alia, methods for methods for treating cancer, compositions for treating cancer, and methods and compositions for diagnosing and/or detecting cancer. In particular, the present invention provides compositions and methods for treating, diagnosing and detecting cancers associated with APCDD1 overexpression.

Abstract: An oral-delivery pharmaceutical composition for reducing the gastric irritation effect of an NSAID in the upper GI tract of a mammal. The composition includes (a) a mucosal protective amount of a pharmaceutically-acceptable hydrocolloid gum obtainable from higher plants, (b) a dispersion-enhancing amount of another excipient and (c) a therapeutically-effective amount of an NSAID. Also disclosed is a process for preparing the composition and a method for reducing the gastric irritation effect of the NSAID by administering the composition. Also, disclosed is a composition particularly useful for preparing an aqueous suspension.